Quality of Life and Late Effects Following Haploidentical Vs. Matched Unrelated Donor Allogeneic Hematopoietic Cell Transplantation: Secondary Analysis of BMT CTN 1702 | Synapse
March 3, 2026
Quality of Life and Late Effects Following Haploidentical Vs. Matched Unrelated Donor Allogeneic Hematopoietic Cell Transplantation: Secondary Analysis of BMT CTN 1702
Key Points
Quality of life varies significantly between haploidentical transplantation and matched unrelated donor transplantation, revealing important disparities.
In a cohort from the BMT CTN 1702 trial, patients reported diverse late effects linked to their donor type, impacting their overall well-being.
Observational analysis across multiple centers explores the nuances of post-transplant experiences, highlighting crucial considerations for future protocols.
Impacts on physical and emotional quality of life suggest the need for tailored approaches in allogeneic transplantation, particularly concerning donor selection.